TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026

Reuters

Dec 04

TScan <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026

TScan Therapeutics Inc. announced it will host a virtual key opinion leader $(KOL)$ event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596376-en) on December 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588702140"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588702140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588702140?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588702140","market":"fut","top_or_hot":-1,"title":"TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TScan Therapeutics Inc. announced it will host a virtual key opinion leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596376-en) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TScan Therapeutics Inc. announced it will host a virtual key opinion leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596376-en) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL7ln8DZ:1","article_id":"2588702140","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588702140","pubTimestamp":1764795913,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TScan Therapeutics Inc. announced it will host a virtual key opinion leader  event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology  Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","TCRX":"Tscan Therapeutics, Inc.","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4539":"次新股"},"translate_title":"TScan Therapeutics公布更新的Alloha 1期试验数据和2026年关键研究计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TCRX":0.9,"NDAQ":0.9},"content_text":"TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026\n    \n\n        TScan Therapeutics Inc. announced it will host a virtual key opinion leader $(KOL)$ event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596376-en) on December 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}